Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fifth Åland Island conference on von Willebrand disease.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Molecular diagnosis of von Willebrand disease.

Haemophilia : the official journal of the World Federation of Hemophilia·2017
Same author

The laboratory diagnosis of haemophilia: Recommendations by the Laboratory Activities Committee of the World Federation of Hemophilia.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

The role of gene therapy in haemophilia.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Confirmation of genetic testing results in haemostasis and thrombosis - survey of current practice in the field.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Genetic testing in bleeding disorders.

Haemophilia : the official journal of the World Federation of Hemophilia·2014

Related Experiment Video

Updated: Jul 13, 2026

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation
08:30

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Published on: August 14, 2017

Type 1 von Willebrand disease.

I Peake1, A Goodeve

  • 1Academic Unit of Haematology, University of Sheffield School of Medicine and Biomedical Science, Sheffield, UK. i.r.peake@sheffield.ac.uk

Journal of Thrombosis and Haemostasis : JTH
|August 1, 2007
PubMed
Summary

Von Willebrand disease (VWD) research has clarified type 1 VWD, identifying von Willebrand factor (VWF) gene mutations as a primary cause. Further research will explore non-VWF genetic and epigenetic factors.

Area of Science:

  • Hematology
  • Genetics
  • Molecular Biology

Background:

  • Von Willebrand factor (VWF) and its role in bleeding disorders have been studied since 1926.
  • VWD classification includes type 3 (severe deficiency), type 2 (functional deficiency), and type 1 (reduced levels).
  • Historically, the genetic basis for type 1 VWD remained unclear, with speculation on other factors like ABO blood groups.

Purpose of the Study:

  • To clarify the genetic etiology of von Willebrand disease (VWD), particularly type 1.
  • To investigate the role of von Willebrand factor (VWF) gene mutations in different VWD types.
  • To identify potential non-VWF genetic or epigenetic factors contributing to VWD.

Main Methods:

  • Phenotypic and genotypic studies of VWD patients.

More Related Videos

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow
11:42

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Published on: July 10, 2017

Pneumococcus Infection of Primary Human Endothelial Cells in Constant Flow
09:34

Pneumococcus Infection of Primary Human Endothelial Cells in Constant Flow

Published on: October 31, 2019

Related Experiment Videos

Last Updated: Jul 13, 2026

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation
08:30

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Published on: August 14, 2017

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow
11:42

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Published on: July 10, 2017

Pneumococcus Infection of Primary Human Endothelial Cells in Constant Flow
09:34

Pneumococcus Infection of Primary Human Endothelial Cells in Constant Flow

Published on: October 31, 2019

  • Gene analysis of the VWF gene.
  • Large-scale population studies in Europe and Canada.

    • Main Results:

    • VWF gene mutations are confirmed as the primary cause for most type 1 VWD cases.
    • Mutations in type 2 and type 3 VWD correlate with functional domains and severe deficiency, respectively.
    • A significant number of type 1 VWD cases lack identified VWF gene mutations.

    Conclusions:

    • VWF gene mutations play a crucial role in the etiology of type 1 VWD, opening new diagnostic and therapeutic avenues.
    • Further research is needed to identify non-VWF genetic and epigenetic factors in VWD.
    • Understanding the genetic basis of VWD subtypes is essential for improved patient management.